Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function—a prespecified substudy from REDUCE-AMI
European Heart Journal - Cardiovascular Pharmacotherapy · 2025
DOI: 10.1093/ehjcvp/pvae062 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2025. Verfasst von Katarina Mars und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sjukhusbacken 10, 188 83, Swe…. Hauptthemen laut MEDLINE: Quality of Life, Adrenergic beta-Antagonists, Ventricular Function, Left, Myocardial Infarction. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Heart Lung Foundation, Swedish Heart and Lung Association, Swedish Research Council.
Abstract (Originalsprache)
Aims
In the Randomized Evaluation of Decreased Usage of Beta-Blockers after Acute Myocardial Infarction (REDUCE-AMI) study, long-term beta-blocker use in patients after acute myocardial infarction (AMI) with preserved left ventricular ejection fraction demonstrated no effect on death or cardiovascular outcomes. The aim of this prespecified substudy was to investigate effects of beta-blockers on self-reported quality of life and well-being. Methods and results From this parallel-group, open-label, registry-based randomized clinical trial, EQ-5D, and World Health Organization well-being index-5 (WHO-5) questionnaires were obtained at 6–10 weeks and 11–13 months after AMI in 4080 and 806 patients, respectively. We report results from intention-to-treat and on-treatment analyses for the overall population and relevant subgroups using Wilcoxon rank sum test and adjusted ordinal regression analyses. Of the 4080 individuals reporting EQ-5D (median age 64 years, 22% female), 2023 were randomized to beta-blockers. The main outcome, median EQ-5D index score, was 0.94 [interquartile range (IQR) 0.88, 0.97] in the beta-blocker group, and 0.94 (IQR 0.88, 0.97) in the no-beta-blocker group 6–10 weeks after AMI, OR 1.00 [95% CI 0.89–1.13; P > 0.9]. After 11–13 months, results remained unchanged. Findings were robust in on-treatment analyses and across relevant subgroups. Secondary outcomes, EQ-VAS and WHO-5 index score, confirmed these results.
Conclusion
Among patients after AMI with preserved left ventricular ejection fraction, self-reported quality of life and well-being was not significantly different in individuals randomized to routine long-term beta-blocker therapy as compared to individuals with no beta-blocker use. These results appear consistent regardless of adherence to randomized treatment and across subgroups which emphasizes the need for a careful individual risk-benefit evaluation prior to initiation of beta-blocker treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sjukhusbacken 10, 188 83, Sweden.
- Department of Women's and Children's Health, Uppsala University, Uppsala 751 85, Sweden.
- Department of Internal Medicine, Ryhov County Hospital, Jönköping 551 85 Sweden.
- Department of Cardiology and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping 581 83, Sweden.
- Division of Cardiology and Emergency medicine, Centralsjukhuset Karlstad, Karlstad 651 82, Sweden.
- Department of Cardiology, Sahlgrenska University Hospital, Gothenburg 405 30, Sweden.
ORCID-Profile: Katarina Mars, Sophia Humphries, Martin Jonsson, Joakim Alfredsson, Annica Ravn-Fischer, Bertil Lindahl, Troels Yndigegn, Claes Held, Robin Hofmann
Förderung
- Swedish Heart Lung Foundation
- Swedish Heart and Lung Association
- Swedish Research Council
Zitieren
APA
Mars, K., Humphries, S., Leissner, P., Jonsson, M., Karlström, P., Lauermann, J., Alfredsson, J., Kellerth, T., Ravn-Fischer, A., Erlinge, D., Lindahl, B., Yndigegn, T., Jernberg, T., Held, C., Olsson, E. M. G., & Hofmann, R. (2025). Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function—a prespecified substudy from REDUCE-AMI. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae062
Vancouver
Mars K, Humphries S, Leissner P, Jonsson M, Karlström P, Lauermann J, et al. Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function—a prespecified substudy from REDUCE-AMI. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvae062
BibTeX
@article{Mars2025,
author = {Mars, Katarina and Humphries, Sophia and Leissner, Philip and Jonsson, Martin and Karlström, Patric and Lauermann, Jörg and Alfredsson, Joakim and Kellerth, Thomas and Ravn-Fischer, Annica and Erlinge, David and Lindahl, Bertil and Yndigegn, Troels and Jernberg, Tomas and Held, Claes and Olsson, Erik M G and Hofmann, Robin},
title = {Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function—a prespecified substudy from REDUCE-AMI},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2025},
doi = {10.1093/ehjcvp/pvae062}
}
EUVIMED